DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20193921

Cystatin C based eGFR - for early detection of diabetic kidney disease

Sudarshan N. Shelke, Jyoti S. Tele

Abstract


Background: Diabetic kidney disease is the leading cause of premature death in young diabetic patients. Detection of diabetic kidney disease as early as possible in the disease process currently offers the best chance of delaying or possibly preventing progression to end-stage renal disease. The present study was aimed to evaluate utility of serum cystatin C based eGFR for early diagnosis of diabetic kidney disease.

Methods: Diagnosed patients of type 2 diabetes mellitus having frank proteinuria were excluded. Patients without proteinuria were tested for microalbuminuria.  50 patients having microalbuminuria were tested for 24 hour urine creatinine, serum creatinine and serum cystatin C. Both cystatin C based eGFR and eGFR by Cockcroft and Gault equation were compared with standard GFR by 24 hour urine Creatinine clearance respectively.

Results: There was statistically significant positive correlation between cystatin C based eGFR and standard GFR by 24 hr Creatinine clearance (r=0.87). For eGFR by Cockcroft-Gault equation, it was 0.36 (r=0.36).

Conclusions: The results of this study suggest that serum cystatin C based eGFR  measurement is a useful, practical tool for the evaluation of renal involvement in the course of diabetes. As serum creatinine values are affected by many factors like age, sex, muscle mass and diet, serum cystatin C based eGFR estimation offers a hope that diabetic kidney disease can be well prevented with appropriate interventions.


Keywords


Cockcroft-Gault equation, Diabetic kidney disease, eGFR, Microalbuminuria, Serum cystatin C

Full Text:

PDF

References


World Health Organization. Prevention of diabetes mellitus. Report of a WHO Study Group. Geneva: World Health Organization; 1994: 844.

Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients the diabetes and aging study. Diabetes Care. 2011;34(6):1329-36.

De Boer IH, Katz R, Cao JJ, Fried LF, Kestenbaum B, Mukamal K, et al. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care. 2009,32(10):1833-8.

Moran A, Palmas W, Field L, Bhattarai J, Joseph E. Schwartz, et al. Cardiovascular Autonomic Neuropathy Is Associated with Microalbuminuria in Older Patients With Type 2 Diabetes . Diabetes Care. 2004 April 27:972-7.

Powers AC. Diabetes mellitus. Faucy As, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine 18th ed, chapter 344, 2968-3003.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(1):S5-10.

American Diabetes Association. Nephropathy in Diabetes. Diabetes Care. 2004;27(1):S79-S83.

Kearney E, Mount J, Watts G, Slavin B, Kind P. Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser. Journal of Clinical Pathol. 1987;40(4):465-8.

Schmidtz A, Vaeth M. Microalbuminuria: A Major Risk Factor in Non‐insulin‐dependent Diabetes. A 10‐year Follow‐up Study of 503 Patients. Diabetic Medicine. 1988;5(2):126-34.

Slot C. Plasma Creatinine Determination A new and specific Jaffe reaction method. Scandanavian J Clin and Laboratory Investigation. 1965;17(4):381-7.

Filler G, Bokenkamp A, Hofmann W. Cystatin C as a marker of GFR-history, indication and future research. Clin Biochem. 2005;38:1-8.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.

Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney int. 2006 Jan 2;69(2):399-405.

Tuttle KR, Stein JH, DeFronzo RA. The natural history of diabetic nephropathy. Semin Neph 10: 184-93,1990.

Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(2),64 -78.

Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz F. Structural-functional relationships in diabetic nephropathy. J Clin Invest, 1984;74:1143-55.

Mogensen C, Christensen C. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J /Wed, 1984;311:89-93.

Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos A, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. The Lancet. 1982 Jun 26;319(8287):1430-2.

Parving HH, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. European Journal of Endocrinology. 1982 Aug 1;100(4):550-5.

Mathiesen E, Oxenboll B, Johansen K, Svendsen P, Deckert T. Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia, 1984 Jun;26(6):406-10.

Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. New England J Medicine. 1989 Apr 13;320(15):966-70.

Mogensen CE, Hansen KW, Sommer S, Klebe J, et al: Microalbuminuria: studies in diabetes, essential hypertension, and renal diseases as compared with the background population. Adv Nephrol, 1991, 20:191-228.

Hansen KW, Mau Pedersen M, Christensen CK, Schmitz A, Christiansen JS, Mogensen CE. Normoalbuminuria ensures no reduction of renal function in type I (insulin-dependent) diabetic patients. J Intern Med, 1992:232(2):161-7.

Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. Journal of Korean medical science. 2011 Feb 1;26(2):258-63.

Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. Journal of the American Society of Nephrology, 2005;16(5);1404-12.

Zhang M, Cao X, Cai G, Wu D, Wei R, Yuan X, Bai X, Liu S, Chen X. Clinical evaluation of serum cystatin C and creatinine in patients with chronic kidney disease: a meta-analysis. J Int Medical Research. 2013 Aug;41(4):944-55.

Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin chemistry. 2007 Mar 1;53(3):480-8.

Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V, et al. determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chemistry. 1994 Oct 1;40(10):1921-6.

Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function Nephrol Dial Transplant. 2006;21:1855-62.

Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am. 2005; 89:457-73.

Choe JY, Park SH, Kim SK. Serum Cystatin C is a potential endogenous marker for the estimation of renal function in male gout patients with renal impairment. J Korean Med Sci. 2010;25(1):42-8.

Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007;27(2): 197-205.

Mojiminiyi OA, Abdella N. Evaluation of cystatin C and beta-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complications. 2003;17(3): 160-8.